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ABSTRACT
Bullous pemphigoid (BP) is an autoimmune blistering skin disorder. Recently, BP induced
by dipeptidyl peptidase-4 (DPP-4) inhibitors has been a concern. Although DPP-4 inhibi-
tors are commonly used in the Asian population because of their safety and efficacy, BP
associated with DPP-4 inhibitors is sometimes seen in clinical settings. Here, we report five
Japanese cases of BP associated with the agents. In the present cases, BP occurred in
older adults using four different DPP-4 inhibitors, which showed various clinical manifesta-
tions in terms of latency period for BP, sex, glycemic control and diabetes duration. With-
drawal of DPP-4 inhibitors was effective in improving BP, and achieved remission even in
cases requiring oral steroid administration and intravenous immunoglobulin therapy. Clini-
cians should note the importance of early diagnosis of this clinical condition and initiate
prompt withdrawal of DPP-4 inhibitors.
INTRODUCTION
Bullous pemphigoid (BP) is an autoimmune blistering skin dis-
order, in which a majority of autoantibodies targets the extra-
cellular non-collagenous 16A domain (NC16A) of
hemidesmosomal collagen XVII1. Of drug-induced BP, BP
associated with dipeptidyl peptidase-4 (DPP-4) inhibitors,
which are known as gliptins, has attracted attention because of
the higher incidence of the adverse effect in comparison with
other drugs2. As DPP-4 inhibitors are the most commonly used
therapy in the Asian population because of their safety and efﬁ-
cacy3, BP associated with DPP-4 inhibitors should be widely
recognized as an adverse event in clinical settings. Here, we
report ﬁve cases of DPP-4 inhibitors-induced BP in Japanese
type 2 diabetes mellitus patients, which occurs mainly in the
elderly. The present cases showed that BP associated with
DPP-4 inhibitors exhibits various manifestations and the
importance of prompt withdrawal of the agents.
CASE PRESENTATION
Case 1
An 81-year-old man with type 2 diabetes mellitus presented
with erythematous tense bullae, which initially appeared on his
thigh and gradually spread over his whole body (Figure 1a).
No mucosal involvement was found. Linagliptin was
introduced 9 months before the onset of skin lesions. Histolog-
ical ﬁndings showed a subepidermal blister, and direct
immunoﬂuorescence analysis showed a linear staining pattern
with complement C3 and immunoglobulin G at the basement
membrane (Figure 1b). Enzyme-linked immunosorbent assay
for BP180-NC16A was positive. The diagnosis of BP was
made, and he was started on 20 mg/day prednisolone. Lina-
gliptin was later suspected as a cause of BP. Remission was
achieved after withdrawal of linagliptin, which was replaced by
insulin. He had sustained remission even while prednisolone
was tapered.
Case 2
An 86-year-old woman with type 2 diabetes mellitus presented
with erythematous tense bullae on her back, which later
speared to her entire body. Linaglitpin was introduced
9 months before the onset of skin lesions. The diagnosis of BP
was made pathologically. The patient was started on 20 mg/day
prednisolone, which was tapered to 2 mg/day over 10 months.
However, tense bullae reappeared and the prednisolone dosage
was increased again. At this point, linagliptin was suspected as
the cause of BP and was discontinued. After switching linaglip-
tin to dulaglutide, remission was achieved.
Case 3
An 83-year-old woman with type 2 diabetes mellitus was trea-
ted with linagliptin for 10 months and then switched to
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CASE REPORT
sitagliptin, with which she was treated for an additional
15 months before erythematous tense bullae appeared. Clinical
diagnosis of BP was conﬁrmed pathologically. The patient was
initially treated with prednisolone (15 mg/day), which was
replaced by intravenous immunoglobulin therapy after 3 days
because of poor control of BP. The skin lesions diminished
consistently after switching from linagliptin to insulin.
Case 4
An 86-year-old woman with type 2 diabetes mellitus treated
with vildagliptin for 6 months presented with erythematous
tense bullae. The clinical diagnosis of BP was conﬁrmed patho-
logically. She was started with 40 mg/day prednisolone and
then received intravenous immunoglobulin due to poor control
of skin symptoms. After switching vildagliptin to insulin, remis-
sion was achieved.
Case 5
A 63-year-old man with type 2 diabetes mellitus treated with
anagliptin for 5 months presented with erythematous bullous
eruptions on his entire body. The clinical diagnosis of BP was
conﬁrmed pathologically. The patient was started on pred-
nisolone (20 mg/day). Anagliptin was switched to repaglinide.
Prednisolone was tapered and stopped within 14 days. Remis-
sion of skin lesions was observed.
DISCUSSION
Bullous pemphigoid has been classically associated with certain
medications, including diuretics, beta-blockers and antibiotics4.
Recently, DPP-4 inhibitors, also called gliptins, were reported as
another causative agent for BP. Although the pathogenic mech-
anism of DPP-4 inhibitors-provoked BP remains unclear, this
adverse drug reaction is reported with multiple gliptins, suggest-
ing a class effect2,5. Actually, the present cases included four of
these agents; linagliptin, sitagliptin, vildagliptin and anagliptin.
To our best knowledge, case 5 is the ﬁrst report of anagliptin-
induced BP. All of the present cases showed persistent cuta-
neous symptoms despite steroid administrations. Improvement
was seen within 2 weeks after cessation of DPP-4 inhibitors,
and sustained remissions were achieved within 2 months
(Table 1). These ﬁndings strongly indicate the causal involve-
ment of DPP-4 inhibitors. The World Health Organization-
Uppsala Monitoring Center criteria for standardized causality
assessment also indicate reasonable causalities in our cases6.
Two retrospective analyses of pharmacovigilance databases
were recently published from Europe2,7. One of the studies
showed no clear relationship between the onset of BP and clini-
cal presentations, such as allergic history, diabetes duration, dia-
betic complications, glycemic control and concomitant
medications or sex2. The mean age of BP onset was relatively
old (74 years), and the latency period for BP from introduction
of DPP-4 inhibitors was relatively long (10 months)2. In the
present cases, the age also tended to be older, while the mean
time from DPP-4 inhibitor administration to BP onset varied
from 5 to 25 months.
A recent study noted BP associated with DPP-4 inhibitors
might present non-inﬂammatory skin symptoms and negative
autoantibodies against BP180-NC16A, which differs from con-
ventional BP8. However, all of the present cases involved
(a)
(b)
Figure 1 | Disseminated bullous eruption with erythema in case 1. (a)
Macroscopic observation. (b) Microscopic observation of the skin
(hematoxylin–eosin, original magnification 920).
Table 1 | Clinical characteristics of the present cases
Patient Age (years)/sex HbA1c levels
at BP diagnosis (%)
DPP-4 inhibitor Latency (months) Titers of BP180NC16A
ELISA (U/mL)
Complete remission
from agent withdrawal (weeks)
Case 1 81/Male 7.6 Linagliptin 9 434 6
Case 2 86/Male 7.4 Linagliptin 9 303 4
Case 3 83/Female 6.8 Linagliptin, Sitagliptin 25 2110 2
Case 4 86/Female 6.3 Vildagliptin 6 182 4
Case 5 63/Male 7.3 Anagliptin 5 305 2
BP, bullous pemphigoid; DPP-4, dipeptidyl peptidase-4; ELISA, enzyme-linked immunosorbent assay; HbA1c, glycated hemoglobin.
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evident erythema and positive autoantibodies against BP180-
NC16A, which could indicate that there is a variety of skin
inﬂammations of BP pathologically associated with the various
DPP-4 inhibitors. Thus, further investigations including a large-
scale epidemiological study are required to determine the clini-
cal characteristics of DPP-4 inhibitors-associated BP.
The present cases also showed the difﬁculty of diagnosis for
DPP-4 inhibitors-associated BP, which is due to the various
clinical manifestations, especially in terms of latency period. As
these features could mask the possible involvement of DPP-4
inhibitors in BP, clinicians should be fully aware of the poten-
tial risk. The present cases show the importance of early diag-
nosis and prompt withdrawal of the agents to avoid
exacerbation of skin symptoms and administration of intra-
venous immunoglobulin or high-dose steroid, which often
results in poor glycemic control. As it took at least 2 weeks to
achieve complete remission, appropriate withdrawal of the
agents is required for remission of BP in suspected cases.
The rising aging population and use of combination drug
therapy including DPP-4 inhibitors requires heightened aware-
ness of DPP-4 inhibitors-induced BP. Once BP has occurred by
DPP-4 inhibitors, appropriate options of antidiabetic agents in
the elderly are limited9,10. However, in the present cases, we
successfully switched DPP-4 inhibitors to insulin, glinide or a
glucagon-like peptide-1 receptor agonist. Any drug, except
DPP-4 inhibitors, can be selected, while paying attention to
hypoglycemia.
In summary, the present cases showed various clinical mani-
festations of DPP-4 inhibitors-induced BP in terms of latency
period, agents and cutaneous inﬂammations. The importance
of early diagnosis of the adverse event should be emphasized,
as the prompt withdrawal of the agent was effective for
improvement of BP.
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